Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | CHKA | P35790 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 4/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5359474 | 0.90 | SYK (0.46) | CHEK1ADORA1SYKPARP1GRM2 | |
| SCHEMBL5359423 | 0.83 | SYK (0.46) | CHEK1ADORA1SYKPARP1PDE2A | |
| SCHEMBL5362996 | 0.80 | PDE2A (0.41) | CHKAPDE2APDE10A | |
| SCHEMBL5355066 | 0.76 | ADORA1 (0.48) | CHEK1ADORA1SYK | |
| SCHEMBL5351179 | 0.75 | ADORA1 (0.45) | ADORA1 | |
| SCHEMBL5358536 | 0.73 | CRBN (0.44) | CHEK1ADORA1 | |
| SCHEMBL5355195 | 0.72 | BRD4 (0.43) | ADORA1 | |
| SCHEMBL5355200 | 0.70 | ADORA1 (0.38) | ADORA1 | |
| SCHEMBL5351538 | 0.69 | ADORA1 (0.44) | ADORA1SYKPDE2A | |
| SCHEMBL5350993 | 0.69 | TNKS (0.42) | ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202245-B2 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | PFIZER INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20040192698-A1 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | PFIZER INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192698-A1 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | CYP4B1, CYP3A4, CYP1B1 | CHEK1 1345/4885ADORA1 12/4885CHKA 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.